We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Low Serum Phosphate Linked to Risk of Heart Attack

By LabMedica International staff writers
Posted on 22 Nov 2017
Print article
Image: Variations in phosphate levels in the blood may pose risk to cardiovascular health (Photo courtesy of Dr. Steve Petryk).
Image: Variations in phosphate levels in the blood may pose risk to cardiovascular health (Photo courtesy of Dr. Steve Petryk).
Cardiovascular disease is a leading cause of mortality and morbidity worldwide, and high serum phosphate is an established risk factor for coronary artery disease, particularly in patients with chronic kidney disease.

Phosphate is an important mineral in the body and helps to regulate blood biochemistry, which can impact on the working of the heart. It plays a crucial role in enabling red blood cells to deliver oxygen to the body's tissues, and can be found in protein rich foods such as meat, poultry and fish.

Scientists at the University of Surrey (Guildford, UK) used data from the Royal College of General Practitioners (RCGP) Research and Surveillance Centre, and examined phosphate levels of more than 100,000 patients, over five and nine-year intervals, and the impact on their cardiac health. Patients aged between 18 and 90 years were included in the study. Influential demographic and physiological variables were identified for each patient as close as possible to time zero and before any cardiac event.

The physiological variables included systolic blood pressure, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, renal function (eGFR), diabetes status and blood markers HbA1c, corrected calcium, sodium, potassium, and albumin. In all cases, single measurements were used except for corrected calcium, which was recorded in a similar manner to serum phosphate with extraction of values recorded on the same dates as serum phosphate.

The investigators found that those with low levels (less than 0.75 mmol/L) of the mineral in their blood were at a similar risk of developing coronary problems as those with elevated levels (above 1.5 mmol/L). Instances of both conditions were high amongst those with low and excessive levels of phosphate in the blood; however cardiac events in those with mid-range (1-1.25 mmol/L) levels were significantly less. The present demonstrated that low, high-normal, and high serum phosphate were associated with primary cardiac disease events in a U-shaped relationship within a general UK population.

Andrew McGovern, MD, a co-author of the study, said, “Our findings shed new light on the role of phosphate in the body and its relationship to cardiovascular health. In light of our findings we would suggest that clinicians consider people with low phosphate levels to be at higher cardiovascular risk and assess ways in which this can be reduced for each patient.” The study was published on November 8, 2017, in the journal Public Library of Science ONE.

Related Links:
University of Surrey

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more